CelLBxHealth plc · LSE:CLBX
CelLBxHealth — ANGLE — H1 2020 Earnings Presentation
12 slides from CelLBxHealth's earnings presentation, Jan 30, 2020
Slide 1: Interim Results for the six months ended 31 October 2019
Interim Results for the six months ended 31 October 2019 Andrew Newland and Ian Griffiths 30 January 2020
Slide 2: Legal disclaimer
LSE AIM: AGL OTCQX: ANPCY Legal disclaimer This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The presentation slides which follow this notice and the oral presentation of whi
Slide 3: Liquid biopsy - improving patient outcomes and reducing healthcare costs
Liquid biopsy - improving patient outcomes and reducing healthcare costs “ANGLE’s mission is to enable personalised cancer care by providing the complete picture of the patient’s cancer from a simple blood test. Simple, effective, affordable repeat testing.” Andrew Newland, Chief Executive Cancer Re
Slide 4: Highlights
Highlights Leading cancer centres Sustained focus on four pronged strategy is delivering clinical studies, regulatory approval, published evidence, and partnerships • Clinical and analytical studies completed in support of FDA clearance for metastatic breast cancer • Ovarian cancer clinical verifica
Slide 5: Financial Results for six months ended 31 October 2019
Financial Results for six months ended 31 October 2019 Six months ended 31 October 2019 2018 Statement of Comprehensive Income £’000 £’000 Comments Revenue 401 273 • Revenue up 47% Cost of sales (101) (69) • Gross margin 75% Gross profit 300 204 Operating costs (6,727) (5,340) • Planned expenditure
Slide 6: FDA clearance: clinical and analytical studies positive results in metastatic breast cancer
FDA clearance: clinical and analytical studies positive results in metastatic breast cancer Seeking first ever FDA clearance for a device to harvest Four leading US cancer centres participating cancer cells from patient blood for subsequent analysis • ahead of known competition with over three years
Slide 7: Full De Novo FDA Submission in preparation
Full De Novo FDA Submission in preparation • FDA Q-Submission made 29 October 2019 • Written response to Q-Submission and meeting with FDA in January 2020 – limited additional analytical studies with contrived samples – already in progress at ANGLE laboratories, no impact on timescales, de minimis a
Slide 8: Ovarian cancer pelvic mass triage test US $1 billion p.a. market potential
Ovarian cancer pelvic mass triage test US $1 billion p.a. market potential • Two 200 patient studies already completed with best in class results AUC >95% accuracy achieved • Sample-to-answer Parsortix® HyCEAD® Ziplex™ optimised • Pre-study results demonstrate potential for high sensitivity and high
Slide 9: Body of published evidence continues to grow
Body of published evidence continues to grow Installed base of c.200 Parsortix® systems in active use • University Medical Centre Hamburg-Eppendorf (UKE) immunotherapy lung cancer >16,000 samples and six new publications in the half year • Disseminated Cancer Cell Network (DCCNet), Parsortix samples
Slide 10: Partnerships with large healthcare companies
Partnerships with large healthcare companies Work has continued to progress corporate partnerships with the potential to: • Expand revenue opportunities for installed base of medtech Solid tissue biopsy is invasive companies from tissue biopsy to blood-based repeat tests – Abbott breast cancer FISH
Slide 11: Building on a leading position in the liquid biopsy market
Building on a leading position in the liquid biopsy market • Highly differentiated solution for the emerging Leading cancer centres $ multi billion liquid biopsy market • Prospect of first ever FDA clearance for harvesting cancer cells for analysis in Q3 CY20 • Ovarian cancer clinical verification s
Slide 12: Investment Highlights
Investment Highlights ANGLE’s Parsortix® system is a simple blood test for personalised cancer Large scale clinical studies in ovarian cancer significantly out-performed care, which harvests viable intact cancer cells (CTCs) for analysis existing standard of care • unique patented microfluidic appro